NO20083187L - Anvendelse av DHA, EPA eller DHA-avledet EPA til behandling av patologi assosiert med cellulaer oksidativ skade - Google Patents

Anvendelse av DHA, EPA eller DHA-avledet EPA til behandling av patologi assosiert med cellulaer oksidativ skade

Info

Publication number
NO20083187L
NO20083187L NO20083187A NO20083187A NO20083187L NO 20083187 L NO20083187 L NO 20083187L NO 20083187 A NO20083187 A NO 20083187A NO 20083187 A NO20083187 A NO 20083187A NO 20083187 L NO20083187 L NO 20083187L
Authority
NO
Norway
Prior art keywords
dha
epa
oxidative damage
derived
pathology associated
Prior art date
Application number
NO20083187A
Other languages
English (en)
Other versions
NO341240B1 (no
Inventor
Juan Carlos Domingo Pedrol
Jose Antonio Villegas Garcia
Original Assignee
Brudy Technology Sl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37728386&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20083187(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from ES200503202A external-priority patent/ES2277557B1/es
Application filed by Brudy Technology Sl filed Critical Brudy Technology Sl
Publication of NO20083187L publication Critical patent/NO20083187L/no
Publication of NO341240B1 publication Critical patent/NO341240B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/361—Carboxylic acids having more than seven carbon atoms in an unbroken chain; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Birds (AREA)
  • Emergency Medicine (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)

Abstract

Den foreliggende oppfinnelse angår anvendelse av en syre anriket på dokosaheksaensyre (DHA) eller eikosapentaensyre (EPA) eller DHA-avledet EPA for fremstilling av et medikament for behandling av prosesser som involverer assosiert oksidativ skade. Særlig er dette for behandling av prosesser assosiert med nevrodegenerative, okulare, iskemiske og inflammatoriske patologier, aterosklerose, med oksidativ skade på DNA og med fysisk trening.
NO20083187A 2005-12-21 2008-07-17 Anvendelse av dokosaheksaensyre (DHA) for fremstilling av et medikament eller en matvare til behandling av en patologi assosiert med cellulær oksidativ skade NO341240B1 (no)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
ES200503202A ES2277557B1 (es) 2005-12-21 2005-12-21 Utilizacion de acido docosahexaenoico para el tratamiento del daño celular oxidativo.
ES200602418A ES2315125B1 (es) 2005-12-21 2006-09-25 Mejoras en el objeto de la patente principal p 200503202, por "utilizacion de acido docosahexaenoico para el tratamiento del daño oxidativo celular".
ES200602417A ES2315124B1 (es) 2005-12-21 2006-09-25 Mejoras en el objeto de la patente principal p 200503202, por "utilizacion de acido docosahexaenoico para el tratamiento del daño oxidativo celular".
ES200603231A ES2316263B1 (es) 2005-12-21 2006-12-20 Mejoras en el objeto de la patente principal p 200503202, por "utilizacion de acido docosahexaenoico para el tratamiento del daño oxidativo celular".
PCT/EP2006/070016 WO2007071733A2 (en) 2005-12-21 2006-12-20 Use of dha, epa or dha-derived epa for treating a pathology associated with cellular oxidative damage

Publications (2)

Publication Number Publication Date
NO20083187L true NO20083187L (no) 2008-09-19
NO341240B1 NO341240B1 (no) 2017-09-25

Family

ID=37728386

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20083187A NO341240B1 (no) 2005-12-21 2008-07-17 Anvendelse av dokosaheksaensyre (DHA) for fremstilling av et medikament eller en matvare til behandling av en patologi assosiert med cellulær oksidativ skade

Country Status (16)

Country Link
US (3) US9265745B2 (no)
EP (3) EP1962825B1 (no)
JP (1) JP2009523414A (no)
KR (1) KR101256448B1 (no)
CN (1) CN101346138B (no)
AU (1) AU2006327064B2 (no)
BR (1) BRPI0621131A2 (no)
CA (1) CA2632949C (no)
ES (1) ES2384701T3 (no)
IL (1) IL192154A (no)
MX (1) MX2008008171A (no)
NO (1) NO341240B1 (no)
NZ (1) NZ569676A (no)
PL (1) PL1962825T3 (no)
RU (1) RU2437583C2 (no)
WO (1) WO2007071733A2 (no)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8252742B2 (en) * 2004-12-30 2012-08-28 Hill's Pet Nutrition, Inc. Methods for enhancing the quality of life of a senior animal
MX2008008171A (es) 2005-12-21 2008-11-12 Brudy Technology S L Uso de dha epa o epa derivado de dha para tratamiento de una patologia asociada al daño celular oxidante.
ES2277557B1 (es) 2005-12-21 2008-07-01 Proyecto Empresarial Brudy, S.L. Utilizacion de acido docosahexaenoico para el tratamiento del daño celular oxidativo.
US20100119600A1 (en) 2007-06-01 2010-05-13 Joar Opheim Substances for reducing occurrence of major cardiac events comprising red yeast rice extract and omega-3 polyunsaturated fatty acid or derivative thereof
US8343753B2 (en) 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
US8207363B2 (en) 2009-03-19 2012-06-26 Martek Biosciences Corporation Thraustochytrids, fatty acid compositions, and methods of making and uses thereof
JP5872453B2 (ja) * 2009-04-17 2016-03-01 ナタク ファルマ エセ．エレ． フィタン酸含量が低く、ω−３脂肪酸に富む組成物
KR20120133381A (ko) 2010-01-19 2012-12-10 디에스엠 아이피 어셋츠 비.브이. 에이코사펜타엔산 생산 미생물, 지방산 조성물 및 이의 제조방법 및 용도
US20120252888A1 (en) * 2011-03-29 2012-10-04 Palupa Medical Ltd. Compositions and Methods for Treating Neurologic Disorders
US10709680B2 (en) * 2011-07-18 2020-07-14 Physicians Recommended Nutriceuticals, Llc Methods for treating dry eye
US20160310456A1 (en) * 2013-03-12 2016-10-27 Physicians Recommended Nutriceuticals, Llc Compositions and methods for using same for reducing levels of arachidonic acid in tissue having undergone an invasive procedure
CN108771240A (zh) 2011-07-21 2018-11-09 帝斯曼知识产权资产管理有限公司 脂肪酸组合物
ES2773310T3 (es) 2013-02-28 2020-07-10 Anida Pharma Inc Métodos para tratamiento de la ototoxicidad
CN103585140A (zh) * 2013-11-22 2014-02-19 苏州麦可旺志生物技术有限公司 Epa在制备溴酸钾诱导氧化应激性肾损伤药物中的应用
CN111154724B (zh) * 2013-12-18 2024-02-06 联邦科学技术研究组织 包含二十二碳六烯酸的提取的植物脂质
US11718577B2 (en) 2013-12-18 2023-08-08 Commonwealth Scientific And Industrial Research Organisation Lipid compositions comprising triacylglycerol with long-chain polyunsaturated fatty acids
EP3906920A1 (en) 2014-06-06 2021-11-10 Marine Ingredients, LLC Omega-3 compositions, dosage forms, and methods of use
KR20180051737A (ko) * 2016-11-08 2018-05-17 차의과학대학교 산학협력단 대장염-관련 암 발생을 줄이는 ω-3 폴리불포화지방산 활성 성분으로 포함하는 항암 조성물
US20170156280A1 (en) 2017-02-13 2017-06-08 Bayer Cropscience Lp Cotton variety st 5517gltp
US20170150690A1 (en) 2017-02-13 2017-06-01 Bayer Cropscience Lp Cotton variety fm 1888gl
JP7133306B2 (ja) * 2017-12-01 2022-09-08 国立大学法人九州大学 アシルステリルグルコシド、アシルステリルグルコシドの製造方法、組成物、抗酸化剤、血中脂質低下剤、抗肥満剤、抗腫瘍剤及びアテローム性動脈硬化症の予防又は治療剤
CN110846346B (zh) * 2019-11-26 2021-06-22 瞿瀚鹏 富含Sn-2位DHA的微生物油脂及其制备方法和应用
CN113749255B (zh) * 2021-09-15 2022-11-29 江南大学 一种磷脂组合物在修复肌肉损伤的应用
WO2023122827A1 (en) * 2021-12-28 2023-07-06 Scf Pharma Inc. Polyunsaturated fatty acid monoglycerides, compositions, methods and uses thereof

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2524217B2 (ja) * 1988-04-18 1996-08-14 マルハ株式会社 脳機能改善組成物、学習能力増強剤、記憶力増強剤、痴呆予防剤または痴呆治療剤
GB2218984B (en) * 1988-05-27 1992-09-23 Renafield Limited Process for preparing high-concentration mixtures of polyunsaturated fatty acids & their esters and their prophylactic or therapeutic uses
GB2223943A (en) 1988-10-21 1990-04-25 Tillotts Pharma Ag Oral disage forms of omega-3 polyunsaturated acids
SE9101642D0 (sv) * 1991-05-30 1991-05-30 Kabi Pharmacia Ab Phospholipids
CA2119000A1 (en) * 1993-03-19 1994-09-20 David Frederick Horrobin Formulation for use in smokers
ATE264099T1 (de) * 1993-06-09 2004-04-15 Martek Biosciences Corp Für die behandlung neurologischer erkrankungen nützliche methoden und pharmazeutische zusammensetzungen
US20050027004A1 (en) * 1993-06-09 2005-02-03 Martek Biosciences Corporation Methods of treating senile dementia and Alzheimer's diseases using docosahexaenoic acid and arachidonic acid compositions
JPH07255417A (ja) * 1994-03-25 1995-10-09 Kanebo Ltd 機能性健康食品
FR2731015B1 (fr) * 1995-02-24 1997-05-30 Sci Sartone Procede d'enrichissement enzymatique d'huiles d'origine marine et les triglycerides d'acides gras polyinsatures ainsi obtenus
DE69637953D1 (de) 1995-04-17 2009-07-30 Nat Inst Of Advanced Ind Scien Hoch ungesättigte fettsäurenproduzierende mikroorganismen und verfahren zur herstellung von hoch ungesättigten fettsäuren durch verwendung dieser mikroorganismen
MY118354A (en) * 1995-05-01 2004-10-30 Scarista Ltd 1,3-propane diol derivatives as bioactive compounds
JP3558423B2 (ja) * 1995-09-11 2004-08-25 旭化成ケミカルズ株式会社 ドコサヘキサエン酸を構成脂肪酸とするリン脂質の製造方法
JP3985035B2 (ja) * 1995-09-14 2007-10-03 独立行政法人産業技術総合研究所 （ｎ−６）系ドコサペンタエン酸含有油脂ならびに該油脂の製造方法および用途
AU3120797A (en) 1996-05-08 1998-07-31 Weider Nutrition Group, Inc. Structured glycerols and structured phosphatides
AU723553C (en) * 1996-07-23 2005-04-14 Nagase & Co., Ltd. Process for preparing docosahexaenoic acid and docosapentaenoic acid
JPH11239464A (ja) * 1997-06-16 1999-09-07 Nippon Suisan Kaisha Ltd 運動時の危険因子除去能を有する組成物
WO1998057628A1 (fr) 1997-06-16 1998-12-23 Nippon Suisan Kaisha, Ltd. Composition capable de supprimer le facteur de risque pendant l'exercice
JPH11239465A (ja) * 1997-06-16 1999-09-07 Nippon Suisan Kaisha Ltd 健常人が運動能力を高める食品
GB9901809D0 (en) * 1999-01-27 1999-03-17 Scarista Limited Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
IT1308613B1 (it) * 1999-02-17 2002-01-09 Pharmacia & Upjohn Spa Acidi grassi essenziali nella prevenzione di eventi cardiovascolari.
JP2002040014A (ja) * 2000-07-19 2002-02-06 Nippon Steel Corp 炭素含有耐火物の耐摩耗性、耐食性及び耐酸化性の評価方法
EP1249523A1 (fr) * 2001-04-12 2002-10-16 Michel Beckers Cylindre brouilleur et son utilisation
ITMI20020269A1 (it) * 2002-02-12 2003-08-12 Victorix Assets Ltd Uso di steri etilici di acidi poliinsaturi omega-3 in pazienti con insufficienza cardiaca
AR039170A1 (es) 2002-03-28 2005-02-09 Bio Dar Ltd Co-granulos de dha y romero y metodos de uso
US20040209953A1 (en) * 2002-12-06 2004-10-21 Wai Lee Theresa Siu-Ling Glyceride compositions and methods of making and using same
US7041840B2 (en) * 2002-12-18 2006-05-09 Alberta Research Council Inc. Antioxidant triacylglycerols and lipid compositions
JP2005000033A (ja) * 2003-06-10 2005-01-06 Shinbijuumu:Kk 食品
GB0314624D0 (en) 2003-06-23 2003-07-30 Advanced Bionutrition Europ Lt Inflammatory disease treatment
AU2004263164A1 (en) 2003-08-05 2005-02-17 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Neuroprotection protects against cellular apoptosis, neural stroke damage, alzheimer's disease and retinal degeneration
JP2005068060A (ja) * 2003-08-22 2005-03-17 Nrl Pharma Inc ラクトフェリンを含有する医薬組成物ならびに加工食品の製造法
US20050130937A1 (en) * 2003-10-22 2005-06-16 Enzymotec Ltd. Lipids containing omega-3 and omega-6 fatty acids
US7842722B2 (en) * 2003-12-19 2010-11-30 Alcon, Inc. Composition and methods for inhibiting the progression macular degeneration and promoting healthy vision
US20050163873A1 (en) 2004-01-14 2005-07-28 Robert Ritch Methods and formulations for treating glaucoma
ITMI20040069A1 (it) 2004-01-21 2004-04-21 Tiberio Bruzzese Uso di composizioni di acidi grassi n-3 ad elevata concentrazione per il trattamento di disturbi del sistema nervoso centrale
US20090054523A1 (en) 2005-01-24 2009-02-26 Morten Bryhn Use of a Fatty Acid Composition Containing DHA for the Production of a Medical Product or a Food Stuff for the Treatment of Amyloidos-Related Diseases
FR2882894B1 (fr) 2005-03-11 2009-04-03 Larena Sa Composition alimentaire suppletive
ES2264886B1 (es) * 2005-05-12 2008-02-01 Proyecto Empresarial Brudy, S.L. Utilizacion de acido docosahexaenoico para el tratamiento de enfermedades tumorales.
MX2008008171A (es) 2005-12-21 2008-11-12 Brudy Technology S L Uso de dha epa o epa derivado de dha para tratamiento de una patologia asociada al daño celular oxidante.

Also Published As

Publication number Publication date
ES2384701T1 (es) 2012-07-11
EP2510927A3 (en) 2013-05-01
MX2008008171A (es) 2008-11-12
NZ569676A (en) 2012-03-30
EP2510927A2 (en) 2012-10-17
RU2008126805A (ru) 2010-01-27
KR101256448B1 (ko) 2013-04-19
PL1962825T3 (pl) 2014-09-30
BRPI0621131A2 (pt) 2011-11-29
AU2006327064B2 (en) 2012-04-26
AU2006327064A1 (en) 2007-06-28
EP1962825B1 (en) 2014-04-02
NO341240B1 (no) 2017-09-25
US20130274337A1 (en) 2013-10-17
CN101346138A (zh) 2009-01-14
US9259408B2 (en) 2016-02-16
IL192154A (en) 2015-04-30
WO2007071733A3 (en) 2007-09-07
EP3263101A1 (en) 2018-01-03
EP1962825A2 (en) 2008-09-03
ES2384701T3 (es) 2014-07-02
KR20080081334A (ko) 2008-09-09
RU2437583C2 (ru) 2011-12-27
WO2007071733A2 (en) 2007-06-28
US20160151258A1 (en) 2016-06-02
US20080292681A1 (en) 2008-11-27
CN101346138B (zh) 2013-03-13
CA2632949A1 (en) 2007-06-28
CA2632949C (en) 2012-05-22
JP2009523414A (ja) 2009-06-25
IL192154A0 (en) 2008-12-29
US9265745B2 (en) 2016-02-23

Similar Documents

Publication Publication Date Title
NO20083187L (no) Anvendelse av DHA, EPA eller DHA-avledet EPA til behandling av patologi assosiert med cellulaer oksidativ skade
MY148603A (en) Use of dha, epa or dha-derived epa for treating a pathology associated with cellular oxidative damage
NO20081067L (no) Behandling med dihydropyndinkalsiumkanalblokkere og omega 3-fettsyrer, og et kombinasjonsprodukt derav
EA201101117A1 (ru) Ингибиторы дпп-4 для лечения диабета у детей
DE502005010615D1 (de) Mittel zur behandlung von entzündlichen erkrankungen
HN2008001771A (es) Esteres de dha
WO2014121298A3 (en) Methods of populating a gastrointestinal tract
PH12015500407B1 (en) Methods of treating hypertriglyceridemia
MY198422A (en) Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
NZ757815A (en) Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
NO20083780L (no) Topisk sammensetning omfattende en antibakteriell substans
DK1970059T3 (da) Lægemiddel med calciumdobesilat til behandling og profylakse af senelidelser
EA201101111A1 (ru) Алкиламинозамещенные дицианопиридины и их пролекарства в виде сложных эфиров с аминокислотами
DE602007006815D1 (de) 4-ä5-methoxy-6-(2-methyl-6-ä1,2,4ütriazol-1-yl-pyridin-3-ylamino)-pyrimidin-4-yloxyü-piperidin-1-carbonsäure isopropyl ester als stoffwechselmodulatore und behandlung von damit assoziierten erkrankungen
EA201190217A1 (ru) Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение
NO341676B1 (no) Tetrahydro-pyrimidoazepiner som modulatorer av TRPVI
EA200970374A1 (ru) Лечение антиаритмическими средствами и омега-3 жирными кислотами и их комбинированным продуктом
UA96794C2 (ru) Глюкокортикоиды, способ их применения, способ лечения и фармацевтическая композиция на их основе
BRPI0812835B8 (pt) combinações e produtos contendo um agente inibidor de vegf e do irinotecano.
WO2017077528A3 (en) Methods and pharmaceutical compositions for treatment of lung inflammation
FR2883182B1 (fr) Composition de vitamines utiles dans le traitement des maladies oculaires
EA201190313A1 (ru) Замещенные пиперидины
DK2435039T4 (da) Kombination af en leucinkilde og en omega-3 umættet fedtsyrekilde til anvendelse i behandling af hypercalcæmi
AR052641A1 (es) Uso de acido docosahexaenoico (dha) y acido araquidonico (ara) para la manufactura de un medicamento para la prevencion o tratamiento de infecciones respiratorias en infantes
DK1979053T3 (da) Produkt til behandling af hud og slimhinder og tilhørende fremgangsmåde til fremstilling

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees